BBLG
Bone Biologics Corporation [BBLG] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BBLG Stock Summary
Top 10 Correlated ETFs
BBLG
Top 10 Correlated Stocks
BBLG
In the News
BBLG Financial details
Company Rating
Neutral
Market Cap
1.47M
Income
-9.51M
Revenue
0
Book val./share
5.44
Cash/share
5.67
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-3.03
Forward P/E
-
PEG
0.04
P/S
-
P/B
3.91
P/C
0.29
P/FCF
-0.27
Quick Ratio
3.76
Current Ratio
4.21
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-84.94
EPS next Y
-
EPS next Q
-
EPS this Y
-332.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-40.82%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-50%
Inst Own
0.07%
Inst Trans
0%
ROA
-98%
ROE
-107%
ROC
-2.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.62-72.0
52W High
-97.74%
52W Low
+63%
RSI
36
Rel Volume
0.85
Avg Volume
87.27K
Volume
74.53K
Perf Week
-2.4%
Perf Month
-32.37%
Perf Quarter
-61.56%
Perf Half Y
-67.14%
-
-
-
-
Beta
0.578
-
-
Volatility
0.07%, 0.3%
Prev Close
-9.19%
Price
1.63
Change
-6.32%
BBLG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -281.85 | -150.43 | -85.11 | 14.62 | -34.01 | |
| Operating cash flow per share | -267.57 | -35.2 | -64.92 | -74.94 | -36.32 | |
| Free cash flow per share | -267.57 | -35.2 | -64.92 | -74.94 | -36.32 | |
| Cash per share | 1.99 | 0 | 352.75 | 158.38 | 11.5 | |
| Book value per share | -976.68 | -1.13K | 347.47 | 124.95 | 11.05 | |
| Tangible book value per share | -976.68 | -1.13K | 347.47 | 124.95 | 11.05 | |
| Share holders equity per share | -976.68 | -1.13K | 347.47 | 124.95 | 11.05 | |
| Interest debt per share | 851.31 | 1.05K | 42.54 | -62.28 | 0 | |
| Market cap | 35.39M | 35.33M | 16M | 2.4M | 1.19M | |
| Enterprise value | 46.69M | 47.06M | 9.33M | -5.14M | -1.84M | |
| P/E ratio | -10.33 | -19.36 | -9.94 | 3.45 | -0.13 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -10.89 | -82.76 | -13.03 | -0.67 | -0.12 | |
| PFCF ratio | -10.89 | -82.76 | -13.03 | -0.67 | -0.12 | |
| P/B Ratio | -2.98 | -2.58 | 2.43 | 0.4 | 0.41 | |
| PTB ratio | -2.98 | -2.58 | 2.43 | 0.4 | 0.41 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -19.08 | -57.04 | -8.47 | 1.17 | 0.19 | |
| EV to operating cash flow | -14.36 | -110.22 | -7.59 | 1.44 | 0.19 | |
| EV to free cash flow | -14.36 | -110.22 | -7.59 | 1.44 | 0.19 | |
| Earnings yield | -0.1 | -0.05 | -0.1 | 0.29 | -7.52 | |
| Free cash flow yield | -0.09 | -0.01 | -0.08 | -1.49 | -8.03 | |
| Debt to equity | -0.95 | -0.86 | 0 | -0.13 | 0 | |
| Debt to assets | 367.21 | 0 | 0 | -0.09 | 0 | |
| Net debt to EBITDA | -4.62 | -14.21 | 6.06 | 1.71 | 0.32 | |
| Current ratio | 0.05 | 0 | 66.81 | 3.33 | 4.5 | |
| Interest coverage | 2.51 | -0.83 | -1.37 | 1.68 | 0 | |
| Income quality | 0.95 | 0.23 | 0.76 | 2.4 | 1.07 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.49K | 1.95K | 815.73 | 202.75 | 91.93 | |
| ROIC | 4.47 | 0.42 | -0.17 | 0.33 | -3.24 | |
| Return on tangible assets | -111.1 | 0 | -0.24 | 0.08 | -2.39 | |
| Graham Net | -977.23 | -1.13K | 347.47 | 107.89 | 8.65 | |
| Working capital | -547.62K | -13.69M | 6.58M | 5.95M | 2.91M | |
| Tangible asset value | -11.87M | -13.69M | 6.58M | 5.95M | 2.91M | |
| Net current asset value | -11.87M | -13.69M | 6.58M | 5.95M | 2.91M | |
| Invested capital | -0.95 | -0.86 | 0 | -0.13 | 0 | |
| Average receivables | 0 | 0 | 0 | 289.96K | 454.38K | |
| Average payables | 84.04K | 254.14K | 282.65K | 50.4K | 180.78K | |
| Average inventory | 0 | 0 | 0 | -289.96K | -454.38K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 313.02K | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.29 | 0.13 | -0.24 | 0.12 | -3.08 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 48.19 | -63.62 | -13.52 | -4.9 | -2.9 | |
| Operating cash flow per share | -30.6 | -20.1 | -27.76 | -6.52 | -3.78 | |
| Free cash flow per share | -30.6 | -20.1 | -27.76 | -6.52 | -3.78 | |
| Cash per share | 118.23 | 92.16 | 53.55 | 11.36 | 5.67 | |
| Book value per share | 93.28 | 41.29 | 43.5 | 9.68 | 5.44 | |
| Tangible book value per share | 93.28 | 41.29 | 43.5 | 9.68 | 5.44 | |
| Share holders equity per share | 93.28 | 41.29 | 43.5 | 9.68 | 5.44 | |
| Interest debt per share | -46.49 | 8.37 | 0 | 0 | 0 | |
| Market cap | 3.21M | 4.17M | 1.5M | 2.23M | 2.41M | |
| Enterprise value | -4.33M | -2.02M | -5.51M | -2.23M | -611.81K | |
| P/E ratio | 0.26 | -0.24 | -0.21 | -0.29 | -0.39 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.65 | -3.09 | -0.41 | -0.87 | -1.2 | |
| PFCF ratio | -1.65 | -3.09 | -0.41 | -0.87 | -1.2 | |
| P/B Ratio | 0.54 | 1.5 | 0.26 | 0.59 | 0.83 | |
| PTB ratio | 0.54 | 1.5 | 0.26 | 0.59 | 0.83 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -4.85 | 0.78 | 1.28 | 1.07 | 0.79 | |
| EV to operating cash flow | 2.22 | 1.5 | 1.52 | 0.87 | 0.3 | |
| EV to free cash flow | 2.22 | 1.5 | 1.52 | 0.87 | 0.3 | |
| Earnings yield | 0.96 | -1.02 | -1.18 | -0.86 | -0.64 | |
| Free cash flow yield | -0.61 | -0.32 | -2.43 | -1.15 | -0.84 | |
| Debt to equity | -0.13 | 0 | 0 | 0 | 0 | |
| Debt to assets | -0.09 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -8.45 | 2.39 | 1.63 | 2.14 | 3.93 | |
| Current ratio | 3.33 | 1.69 | 3.95 | 4.21 | 4.5 | |
| Interest coverage | 0.59 | -5.6 | 0 | 0 | 0 | |
| Income quality | -2.18 | 0.36 | 2.05 | 1.33 | 1.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 318.02 | 243.12 | 115.02 | 32.67 | 18.84 | |
| ROIC | -0.86 | -1.31 | -0.53 | -0.55 | -0.4 | |
| Return on tangible assets | 0.36 | -0.63 | -0.23 | -0.39 | -0.41 | |
| Graham Net | 80.54 | 32.42 | 38.8 | 8.34 | 4.26 | |
| Working capital | 5.95M | 2.77M | 5.69M | 3.79M | 2.91M | |
| Tangible asset value | 5.95M | 2.77M | 5.69M | 3.79M | 2.91M | |
| Net current asset value | 5.95M | 2.77M | 5.69M | 3.79M | 2.91M | |
| Invested capital | -0.13 | 0 | 0 | 0 | 0 | |
| Average receivables | 289.96K | 289.96K | 0 | 0 | 164.42K | |
| Average payables | 843.97K | 1.58M | 1.98M | 1.4M | 731.69K | |
| Average inventory | -289.96K | -289.96K | 0 | 0 | -164.42K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.52 | -1.54 | -0.31 | -0.51 | -0.53 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BBLG Frequently Asked Questions
What is Bone Biologics Corporation stock symbol ?
Bone Biologics Corporation is a US stock , located in Burlington of Ma and trading under the symbol BBLG
What is Bone Biologics Corporation stock quote today ?
Bone Biologics Corporation stock price is $1.63 today.
Is Bone Biologics Corporation stock public?
Yes, Bone Biologics Corporation is a publicly traded company.
Company Profile
- Volume Average 87.27K
- Market Capitalization 1.47M
- Employee 2
- CEO Mr. Jeffrey Frelick
- Headquarters Burlington,MA,US
- IPO Date 2021-10-13
-
Website
https://www.bonebiologics.com 
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
